Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547677 | 0.85 | PPARD (0.44) | PPARDPPARAALOX5PPARGLRRK2 | |
| SCHEMBL12384370 | 0.81 | PTPN1 (0.43) | PPARDLRRK2PTPN1 | |
| SCHEMBL2293313 | 0.79 | PPARD (0.47) | CYP11B1CYP11B2CYP19A1PPARDPPARA | |
| SCHEMBL12384391 | 0.79 | SLC1A5 (0.37) | PPARDPPARAPTGESPPARGHTR2C | |
| Bromide SCHEMBL2296471 | 0.79 | PPARD (0.48) | CYP11B1CYP11B2CYP19A1PPARDPPARA | |
| SCHEMBL4603133 | 0.78 | HTR2A (0.39) | PPARDALOX5PSEN1SLC6A4 | |
| SCHEMBL12384381 | 0.78 | MAOB (0.42) | PPARDLRRK2PTPN1 | |
| SCHEMBL12384374 | 0.76 | L3MBTL1 (0.47) | LRRK2 | |
| SCHEMBL12384351 | 0.75 | SLC6A4 (0.44) | PTPN1SLC6A4 | |
| SCHEMBL12384331 | 0.74 | PTPN1 (0.45) | PPARDALOX5PTPN1PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | CYP11B1 7/4885CYP11B2 6/4885CYP19A1 803/4885 |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | CYP11B1 393/4885CYP11B2 345/4885CYP19A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.